BioInvent Interim Report 1 January – 31 March 2014

Regulatory News:

BioInvent (STO:BINV) rights issue was oversubscribed and business development activity is high

First quarter

· Net sales for January – March 2014 amounted to SEK 1.8 (12) million.

· Earnings after tax for January – March 2014: SEK -19 (-14) million. Earnings per share before and after dilution SEK -0.22 (-0.19).

· Liquid funds as of 31 March 2014: SEK 42 (77) million. Including proceeds of the new share issue liquid funds pro forma would have amounted to SEK 99 million. Cash flow of current operations and investment activities for January – March 2014: SEK -23 (-23) million.

Important events in the first quarter

· BioInvent initiated a new share issue of in total SEK 63.9 million in the first quarter. The rights issue was completed in the second quarter and was oversubscribed by 101%. The rights issue of SEK 48.9 million was supplemented with a private placement of SEK 15 million to Henrik Rhenman through Rhenman Healthcare Equity L / S and Peter Thelin through East Bay AB.

Comments from the CEO

"I am very pleased with the successful new share issue and also the positive response I have met from investors. There is an increasing confidence in BioInvent and in our short and long term potential. There are now intensive efforts to generate new agreements and partnerships in conjunction with new clinical studies for our key projects BI-505 and BI-1206." says Michael Oredsson, CEO of BioInvent.

The report is also available at www.bioinvent.com

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Les Laboratoires Servier and Mitsubishi Tanabe Pharma.

Information disclosed in this interim report statement is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 6 May, 2014.

This information was brought to you by Cision http://news.cision.com